Endo Pharms patents expiration
1. Fortesta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6319913 | ENDO PHARMS | Penetration enhancing and irritation reducing systems |
Nov, 2018
(5 years ago) | |
| US6579865 | ENDO PHARMS | Penetration enhancing and irritation reducing systems |
Nov, 2018
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 29, 2013 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 29 December, 2010
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: GEL, METERED;TRANSDERMAL
FORTESTA family patents
2. Frova patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5962501 | ENDO PHARMS | Enantiomer of carbazole derivative as 5-HT1-like agonists |
Dec, 2013
(10 years ago) | |
| US5616603 | ENDO PHARMS | Enantiomers of carbazole derivatives as 5-HT1 -like agonists |
Apr, 2014
(10 years ago) | |
| US5637611 | ENDO PHARMS | Medicaments |
Jun, 2014
(9 years ago) | |
| US5827871 | ENDO PHARMS | Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT1 agonist use thereof |
Oct, 2015
(8 years ago) | |
| US5464864 | ENDO PHARMS | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists |
Nov, 2015
(8 years ago) | |
Drugs and Companies using FROVATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 08 November, 2001
Treatment: Acute treatment of migraine attacks with or without aura in adults
Dosage: TABLET;ORAL
FROVA family patents
3. Opana Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851482 | ENDO PHARMS | Method for making analgesics |
Jul, 2029
(5 years from now) | |
| US8871779 | ENDO PHARMS | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
Nov, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5662933 | ENDO PHARMS | Controlled release formulation (albuterol) |
Sep, 2013
(10 years ago) | |
| US5958456 | ENDO PHARMS | Controlled release formulation (albuterol) |
Sep, 2013
(10 years ago) | |
| US8329216 | ENDO PHARMS | Oxymorphone controlled release formulations |
Feb, 2023
(1 year, 2 months ago) | |
| US7276250 | ENDO PHARMS | Sustained release formulations of oxymorphone |
Feb, 2023
(1 year, 2 months ago) | |
| US8309122 | ENDO PHARMS | Oxymorphone controlled release formulations |
Feb, 2023
(1 year, 2 months ago) | |
| US8309112 | ENDO PHARMS | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
Feb, 2023
(1 year, 2 months ago) | |
| US8075872 | ENDO PHARMS | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8309060 | ENDO PHARMS | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8114383 | ENDO PHARMS | Abuse-proofed dosage form |
Aug, 2024
(3 months from now) | |
| US8192722 | ENDO PHARMS | Abuse-proof dosage form |
Sep, 2025
(1 year, 4 months from now) | |
| US8808737 | ENDO PHARMS | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
Jun, 2027
(3 years from now) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 June, 2006
Treatment: Relief of moderate to severe pain; Method of administration of controlled release oxymorphone
Dosage: TABLET, EXTENDED RELEASE;ORAL
OPANA ER family patents